Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Pancreatic cancer
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 …
Importance National guidelines endorse treatment with neoadjuvant therapy for borderline
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …
resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains …
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
AJ Grossberg, LC Chu, CR Deig… - CA: a cancer journal …, 2020 - Wiley Online Library
Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …
the prognosis for this disease remains very poor, largely because of delayed disease …
[HTML][HTML] International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
This statement was developed to promote international consensus on the definition of
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …
borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) which was adopted by …
Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology
MA Tempero, MP Malafa, M Al-Hawary… - Journal of the National …, 2017 - jnccn.org
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …
quality multiphase imaging can help to preoperatively distinguish between patients eligible …
Pancreatic ductal adenocarcinoma: current and evolving therapies
A Adamska, A Domenichini, M Falasca - International journal of molecular …, 2017 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …
the fourth leading cause of cancer-related deaths in the world. Due to the broad …
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis
QP Janssen, S Buettner, M Suker… - JNCI: Journal of the …, 2019 - academic.oup.com
Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …
Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in …
Importance Although consensus statements support the preoperative treatment of borderline
resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this …
resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this …